Skip to main content
. 2022 Jan 18;10(4):669–676. doi: 10.1111/andr.13153

TABLE 3.

Proportion of subjects achieving T Cmax within the target criteria at end of study, safety set (N = 95)

Proportion of subjects post‐treatment
T Cmax criteria Secondary efficacy target TLANDO
≤ 1.5 × ULN* ≥ 85% 82%
Between 1.8 × and 2.5 × ULN* ≤ 5% 5%
>2.5 × ULN* 0% 0%
*

ULN is 1080 ng/dl: 1.5 × ULN = 1620 ng/dl, 1.8 × ULN = 1944 ng/dl, and 2.5 × ULN = 2700 ng/dl.